CCL2 (pM levels) as a therapeutic agent in Inflammatory Bowel Disease models in mice.

abstract：BACKGROUND:The consistency of endoscopic and histologic findings in patients with ulcerative colitis (UC) has not been elucidated. Choice of assessment may affect study outcomes. METHODS:Post hoc analyses were performed using data from 2 randomized, controlled multicenter trials: (1) SAG-26, mesalazine granules for in...

journal_title：Inflammatory bowel diseases

authors： Wolff S,Terheggen G,Mueller R,Greinwald R,Franklin J,Kruis W

更新日期：2013-11-01 00:00:00

abstract：:Induction and maintenance of remission, mucosal healing, the avoidance of surgical intervention, and decreasing the likelihood of cancer developing are the primary therapeutic goals in ulcerative colitis (UC). For the traditional therapies, 5-aminosalicylic acid (including mesalamine), corticosteroids, and thiopurines...

journal_title：Inflammatory bowel diseases

authors： Ng SC,Kamm MA

更新日期：2009-06-01 00:00:00

abstract：BACKGROUND:Recently, granulocyte and monocyte adsorption apheresis (GCAP) has been shown to be safe and effective for active ulcerative colitis (UC). We analyzed the safety and efficacy of GCAP (G-1 Adacolumn) in patients with steroid-refractory and -dependent UC. G-1 Adacolumn is filled with cellulose acetate carriers...

journal_title：Inflammatory bowel diseases

authors： Naganuma M,Funakoshi S,Sakuraba A,Takagi H,Inoue N,Ogata H,Iwao Y,Ishi H,Hibi T

更新日期：2004-05-01 00:00:00

abstract：BACKGROUND:Mesalamine, 5-aminosalicylic acid (5-ASA), is a potent antioxidant and is known to enhance peroxisome proliferator-activated receptor γ activity in the intestine. Our previous studies suggested reduced Phosphoinositide 3-Kinase (PI3K)/β-catenin signaling as a mechanism for 5-ASA chemoprevention in chronic ul...

journal_title：Inflammatory bowel diseases

authors： Managlia E,Katzman RB,Brown JB,Barrett TA

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Mucosal expression of interferon (IFN)-γ plays a pivotal role in the pathogenesis of inflammatory bowel disease (IBD) and IBD risk regions flank IFNG. The conserved IFNG rs1861494 T/C introduces a new CpG methylation site, is associated with disease severity and lack of therapeutic response in other infectio...

journal_title：Inflammatory bowel diseases

authors： Gonsky R,Deem RL,Landers CJ,Haritunians T,Yang S,Targan SR

更新日期：2014-10-01 00:00:00

abstract：:The role of endoscopy in inflammatory bowel disease (IBD) has grown over the last decade in both diagnostic and therapeutic realms. It aids in the initial diagnosis of the disease and also in the assessment of the extent and severity of disease. IBD is associated with development of multiple complications such as stri...

journal_title：Inflammatory bowel diseases

authors： Tharian B,George N,Navaneethan U

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Although infliximab is widely accepted as a therapeutic option for inflammatory bowel disease, its therapeutic efficacy for the treatment of intestinal Behçet's disease (BD) is unknown. We investigated the short-term and long-term response rates to infliximab in intestinal BD and predictive factors of sustai...

journal_title：Inflammatory bowel diseases

authors： Lee JH,Cheon JH,Jeon SW,Ye BD,Yang SK,Kim YH,Lee KM,Im JP,Kim JS,Lee CK,Kim HJ,Kim EY,Kim KO,Jang BI,Kim WH

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Assimilation of the preferred nutrient of enterocytes is mediated primarily by sodium (Na)-dependent cotransport (NGct) in the intestine. The predominant NGcT in villus cells, B0AT1, is inhibited secondary to a decrease in cotransporter numbers during chronic intestinal inflammation. In contrast, NGcT mediat...

journal_title：Inflammatory bowel diseases

authors： Arthur S,Saha P,Sundaram S,Kekuda R,Sundaram U

更新日期：2012-11-01 00:00:00

abstract：BACKGROUND:CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone....

journal_title：Inflammatory bowel diseases

authors： Reinisch W,Panaccione R,Bossuyt P,Baert F,Armuzzi A,Hébuterne X,Travis S,Danese S,Sandborn WJ,Schreiber S,Berg S,Zhou Q,Kligys K,Neimark E,Suleiman AA,D'Haens G,Colombel JF

更新日期：2020-09-18 00:00:00

abstract：BACKGROUND:Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC. METHODS:In a multicenter, double-blind, randomized study, 229 patients with mild-to-moderate active ...

journal_title：Inflammatory bowel diseases

authors： Ito H,Iida M,Matsumoto T,Suzuki Y,Sasaki H,Yoshida T,Takano Y,Hibi T

更新日期：2010-09-01 00:00:00

abstract：BACKGROUND:Genetic variants of nucleotide-binding oligomerization domain 2 (NOD2) lead to aberrant microbial recognition and can cause chronic inflammatory diseases in patients with Crohn's disease (CD). METHODS:We utilized gene-specific siRNA mediated knockdown and expression of guanine nucleotide exchange factor H1 ...

journal_title：Inflammatory bowel diseases

authors： Zhao Y,Alonso C,Ballester I,Song JH,Chang SY,Guleng B,Arihiro S,Murray PJ,Xavier R,Kobayashi KS,Reinecker HC

更新日期：2012-04-01 00:00:00

abstract：:MicroRNAs (miRNAs) are single-stranded RNA molecules, which influence the translation of messenger RNA and hence protein synthesis. The altered expression of miRNAs in disease states in cancer and autoimmune diseases including inflammatory bowel disease is providing new insights into disease pathogenesis. This underst...

journal_title：Inflammatory bowel diseases

authors： Whiteoak SR,Felwick R,Sanchez-Elsner T,Fraser Cummings JR

更新日期：2015-05-01 00:00:00

abstract：BACKGROUND:The efficacy of anti-tumor necrosis factor monoclonal antibody (anti-TNF mAb) for Crohn's disease (CD) is well established, and anti-interleukin-6 receptor (anti-IL-6R) mAb has also been reported to be effective in CD. It is, however, unclear if the efficacy and mechanisms of both agents are different in CD ...

journal_title：Inflammatory bowel diseases

authors： Terabe F,Fujimoto M,Serada S,Shinzaki S,Iijima H,Tsujii M,Hayashi N,Nomura S,Kawahata H,Jang MH,Miyasaka M,Mihara M,Ohsugi Y,Kishimoto T,Naka T

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Infliximab (IFX) infusion may lead to development of anti-IFX antibodies, and subsequent infusion reactions (IRs). The safety of rapid IFX infusion administered over 60 minutes has been under-investigated in children with inflammatory bowel disease. In a multicenter study, the frequency and nature of rapid i...

journal_title：Inflammatory bowel diseases

authors： El-Matary W,Dykes DMH,Bauman L,Elkadri A,Carroll MW,Izaguirre MR,deBruyn J,Samson CM,Crim AM,Ali S,Grossman A

更新日期：2017-12-01 00:00:00

abstract：BACKGROUND:The aim of the study was to assess perianal fistulas by magnetic resonance imaging (MRI) in patients with severe fistulizing Crohn's disease (CD) using maintenance antitumor necrosis factor alpha (TNF-α) therapy and to correlate MRI changes with clinical outcome. METHODS:Perineal MRI before and after a 1-ye...

journal_title：Inflammatory bowel diseases

authors： Savoye-Collet C,Savoye G,Koning E,Dacher JN,Lerebours E

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:Anti-tumor necrosis factor-α (anti-TNF-α) treatments are increasingly used to treat pediatric Crohn's disease, even without a prior trial of immunomodulators, but the cost-effectiveness of such treatment algorithms has not been formally examined. Drug plan decision-makers require evidence of cost-effectivene...

journal_title：Inflammatory bowel diseases

authors： Bashir NS,Walters TD,Griffiths AM,Ito S,Ungar WJ

更新日期：2020-07-17 00:00:00

abstract：BACKGROUND:Advanced oxidation protein products (AOPPs) are new protein markers of oxidative stress with pro-inflammatory properties, accumulated in many pathological conditions. The issue of their enhanced formation in IBD has not been addressed yet. METHODS:The concentration of relative AOPPs (rAOPP; concentration of...

journal_title：Inflammatory bowel diseases

authors： Krzystek-Korpacka M,Neubauer K,Berdowska I,Boehm D,Zielinski B,Petryszyn P,Terlecki G,Paradowski L,Gamian A

更新日期：2008-06-01 00:00:00

abstract：:Skin manifestations are common in patients suffering from inflammatory bowel disease (IBD) and can be associated with the disease itself, with nutritional deficiencies, or with therapy. All drugs currently used for treating IBD have the potential to cause dermatologic manifestations that can have a wide range of clini...

journal_title：Inflammatory bowel diseases

authors： Torres J,Buche S,Delaporte E,Colombel JF

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:Chronic ulcerative colitis (UC) is associated with an increased colorectal cancer risk which may be secondary to repetitive mucosal injury. Both epigenetic methylation and the classic adenoma-to-carcinoma sequence have been implicated in this malignant transformation, but the underlying molecular mechanisms ...

journal_title：Inflammatory bowel diseases

authors： Sanchez JA,Dejulius KL,Bronner M,Church JM,Kalady MF

更新日期：2011-09-01 00:00:00

abstract：:: Patients with ulcerative colitis are at increased risk for colorectal adenocarcinoma compared with the general population. Although surveillance for colorectal malignancy and dysplasia (a premalignant lesion) has been recommended, a benefit in reducing mortality from colorectal cancer via surveillance or prophylacti...

journal_title：Inflammatory bowel diseases

authors： Giardiello FM,Gurbuz AK,Bayless TM,Goodman SN,Yardley JH

更新日期：1996-04-01 00:00:00

abstract：BACKGROUND:The use of stress management psychotherapy is hypothesized to produce greater improvement in disease course and disease-specific quality of life (IBDQ) compared to usual medical care alone in patients with ulcerative colitis (UC) or Crohn's disease (CD) showing high levels of stress (based on the Perceived S...

journal_title：Inflammatory bowel diseases

authors： Boye B,Lundin KE,Jantschek G,Leganger S,Mokleby K,Tangen T,Jantschek I,Pripp AH,Wojniusz S,Dahlstroem A,Rivenes AC,Benninghoven D,Hausken T,Roseth A,Kunzendorf S,Wilhelmsen I,Sharpe M,Blomhoff S,Malt UF,Jahnsen J

更新日期：2011-09-01 00:00:00

abstract：Background:We assessed the comparative efficacy of different dysplasia detection techniques in patients with ulcerative colitis (UC) through a network meta-analysis and rated the quality of evidence using GRADE approach. Methods:Through a systematic literature review of multiple databases through June 30, 2017, we ide...

journal_title：Inflammatory bowel diseases

authors： Bessissow T,Dulai PS,Restellini S,Landry T,Bisschops R,Murad MH,Singh S

更新日期：2018-11-29 00:00:00

abstract：BACKGROUND:Our objectives were to assess the differences in perforating disease behavior, disease severity, and extraintestinal manifestations (EIM) in patients with Crohn's disease (CD) by race. MATERIALS AND METHODS:We identified outpatients with CD evaluated at the University of Maryland Gastroenterology Faculty Pr...

journal_title：Inflammatory bowel diseases

authors： Cross RK,Jung C,Wasan S,Joshi G,Sawyer R,Roghmann MC

更新日期：2006-03-01 00:00:00

abstract：BACKGROUND:Fatigue is highly prevalent among patients with inflammatory bowel disease (IBD) and may have an unfavorable impact on quality of life (QoL). The IBD-Fatigue scale (with components SCORE1 and SCORE2) is a recently developed disease-specific questionnaire. We sought to validate a Greek version of IBD-F and us...

journal_title：Inflammatory bowel diseases

authors： Varbobitis I,Kokkotis G,Gizis M,Perlepe N,Laoudi E,Bletsa M,Bekiari D,Koutsounas I,Kounadis G,Xourafas V,Lagou S,Kolios G,Papakonstantinou I,Bamias G

更新日期：2020-08-07 00:00:00

abstract：:Crohn and Rosenberg first highlighted the increased risk of colorectal cancer in ulcerative colitis in 1925. Cancer rates as high as 34 percent after 30 yrs of disease have been reported in several population-based studies, although the reported risk varies substantially. Lower rates have been reported in: population-...

journal_title：Inflammatory bowel diseases

authors： Allen PB,Kamm MA,De Cruz P,Desmond PV

更新日期：2010-11-01 00:00:00

abstract：BACKGROUND:As the American population is aging, the number of older people with inflammatory bowel disease is increasing. We used clinical data from the Sinai-Helmsley Alliance for Research Excellence (SHARE), a prospective cohort, to examine disease and treatment differences in older adults. METHODS:We performed a cr...

journal_title：Inflammatory bowel diseases

authors： Kochar B,Long MD,Galanko J,Raffals LE,Ananthakrishnan A,Sandler RS

更新日期：2017-07-01 00:00:00

abstract：:Anorexia, malnutrition, altered body composition and development of mesenteric obesity are well known features of inflammatory bowel disease (IBD). Recent data suggest that dysregulation of protein secretion by white adipose tissue is involved in these manifestations of patients with IBD. Adipocytes are recently recog...

journal_title：Inflammatory bowel diseases

authors： Karmiris K,Koutroubakis IE,Kouroumalis EA

更新日期：2005-09-01 00:00:00

abstract：BACKGROUND:This study examines the resources utilization in patients with Crohn's disease (CD) during the year before (Y - 1) and after (Y + 1) starting treatment with adalimumab and the drug's efficiency. METHODS:Observational, multicenter, prospective cohort study of patients with CD naive to biological drugs. The p...

journal_title：Inflammatory bowel diseases

authors： Saro C,Ceballos D,Muñoz F,De la Coba C,Aguilar MD,Lázaro P,Iglesias-Flores E,Barreiro-de Acosta M,Hernández-Durán MD,Barrio J,Riestra S,Fernández Salazar L,EFICADEC Researchers Group.

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:The women's health aspect of inflammatory bowel disease (IBD) is a newer area of study; childbearing issues have received little attention despite the fact that IBD affects women predominantly during their childbearing years. The aim of this study was to better understand patients' considerations about pregn...

journal_title：Inflammatory bowel diseases

authors： Marri SR,Ahn C,Buchman AL

更新日期：2007-05-01 00:00:00

abstract：:Corticosteroids, and more recently biologics, have been the mainstay of therapy for patients with inflammatory bowel disease. Unfortunately, both are fraught with side effects and limited by lack of efficacy or loss of response. Many patients ultimately succumb to medically refractory disease and require an operation....

journal_title：Inflammatory bowel diseases

authors： Lightner AL

更新日期：2018-07-12 00:00:00